Chinese antibody maker nets $160 million in Series B
Shanghai-based Genor Biopharma completed its Series B last week, raising $160 million in a funding round that was led by private equity group Hillhouse Capital.
Founded in 2007, the clinical stage drug company specializes in developing antibodies to treat cancer and autoimmune diseases.
With three of its drugs in Phase 3 trials and a PD-1 inhibitor in four pivotal Phase 2 trials, Genor’s pipeline attracted a diverse panel of investors in this latest round of financing, including Singapore-owned Temasek Holdings, Shanghai-based Haitong Capital, and CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group.
Last December, Bloomberg reported that Genor was planning an IPO on the Hong Kong Stock Exchange to raise about $200 million.
Founded in 2007, the clinical stage drug company specializes in developing antibodies to treat cancer and autoimmune diseases.
With three of its drugs in Phase 3 trials and a PD-1 inhibitor in four pivotal Phase 2 trials, Genor’s pipeline attracted a diverse panel of investors in this latest round of financing, including Singapore-owned Temasek Holdings, Shanghai-based Haitong Capital, and CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group.
Last December, Bloomberg reported that Genor was planning an IPO on the Hong Kong Stock Exchange to raise about $200 million.
.png)
No hay comentarios:
Publicar un comentario